08 August 2020>: Clinical Research
Protective Effect of Probiotics against Esophagogastric Variceal Rebleeding in Patients with Liver Cirrhosis after Endoscopic Therapy
Qun Zhang 1CDE , Fangyuan Gao 1CD , Xue Yang 1D , Ying Hu 1D , Yao Liu 1CD , Yixin Hou 1D , Yuxin Li 1D , Bingbing Zhu 2B , Shuaishuai Niu 1BF , Yunyi Huang 3B , Xianbo Wang 1ADG*DOI: 10.12659/MSM.924040
Med Sci Monit 2020; 26:e924040
Table 4 Risk factor of probiotics dose for esophagogastric variceal rebleeding.
Probiotics dose group | n | Rebleeding n (%) | AHR* (95% CI) | P-value |
---|---|---|---|---|
490 | 261 (53.3) | 1.0 | – | |
28–60 cDDD group | 73 | 36 (49.3) | 0.755 (0.529–1.078) | 0.123 |
61–90 cDDD group | 98 | 43 (43.9) | 0.629 (0.452–0.874) | 0.008 |
>90 cDDD group | 43 | 16 (37.2) | 0.442 (0.265–0.737) | 0.002 |
for trends | 0.001 | |||
AHR – adjusted hazard ratio; CI – confidence interval. * AHR represents multivariate-adjusted hazard ratio: etiology, comorbidity index, Child-Pugh class, MELD score, ALT, AST, TBIL, GGT, CREA, GLU, WBC, INR, secondary prophylaxis are adjusted using a Cox proportional hazard regression model. |